Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Disrupting the tumour microenvironment with radiopharmaceutical therapy

FY 2023-24

Summary
The tumor microenvironment is a key determinant of cancer cell survival and cancer progression. In addition to driving cancer cell adaptation, cancer stroma supports the growth of metastasis via immune and mesenchymal cell infiltration, which can promote metastasis and induce chemotherapy resistance. Several radiotracers targeting cancer cells and/or the tumor microenvironment are being developed for radiopharmaceutical therapy (RPT) of metastatic cancers. Examples include novel compounds for targeting tumor hypoxia (CA-IX), tumor stroma (fibroblast activation protein), and the CXCR4 chemokine receptor. CXCR4 is commonly expressed in cytokine receptor in human malignancies and is also present in inflammatory, vascular, and stromal cells. The proposed project will involve mapping of tissues using immunocompetent syngeneic cancer models for the distribution of target cells (MC1R, CXRC4, CA-IX, S100), target proteins in the tumor microenvironment (FAP, CXR4), immune and vascular cells using validated panel of fluorescent antibodies. Following validation, experiments using tissue sections from in vivo models injected with radiopharmaceuticals of interest will be conducted, following imaging with high-resolution ex vivo autoradiography and multiplex immunofluorescence. We will perform these studies using syngeneic immunocompetent mouse cancer models of lymphoma and melanoma. This work will improve our understanding of the spatial relationship between radioactive drug deposition, tissue damage, and response to RPT. The overall aim of the proposed project is to inform the design of combination therapies using RPT, improve our understanding of radiation microdosimetry using radiopharmaceuticals, and improve the efficacy of RPT in achieving effective cancer control.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
506046
Name
Friesen Emma G
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Disrupting the tumour microenvironment with radiopharmaceutical therapy
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Cxcr4 Chemokine Receptor; Lymphoma; Melanoma; Metastatic Cancer; Microdosimetry; Mouse Model; Radiography; Radiopharmaceutical; Tumor Microenvironment
Abstract
The tumor microenvironment is a key determinant of cancer cell survival and cancer progression. In addition to driving cancer cell adaptation, cancer stroma supports the growth of metastasis via immune and mesenchymal cell infiltration, which can promote metastasis and induce chemotherapy resistance. Several radiotracers targeting cancer cells and/or the tumor microenvironment are being developed for radiopharmaceutical therapy (RPT) of metastatic cancers. Examples include novel compounds for targeting tumor hypoxia (CA-IX), tumor stroma (fibroblast activation protein), and the CXCR4 chemokine receptor. CXCR4 is commonly expressed in cytokine receptor in human malignancies and is also present in inflammatory, vascular, and stromal cells. The proposed project will involve mapping of tissues using immunocompetent syngeneic cancer models for the distribution of target cells (MC1R, CXRC4, CA-IX, S100), target proteins in the tumor microenvironment (FAP, CXR4), immune and vascular cells using validated panel of fluorescent antibodies. Following validation, experiments using tissue sections from in vivo models injected with radiopharmaceuticals of interest will be conducted, following imaging with high-resolution ex vivo autoradiography and multiplex immunofluorescence. We will perform these studies using syngeneic immunocompetent mouse cancer models of lymphoma and melanoma. This work will improve our understanding of the spatial relationship between radioactive drug deposition, tissue damage, and response to RPT. The overall aim of the proposed project is to inform the design of combination therapies using RPT, improve our understanding of radiation microdosimetry using radiopharmaceuticals, and improve the efficacy of RPT in achieving effective cancer control.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Friesen, Emma G
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~